← Back to Screener
Vaxcyte, Inc. Common Stock (PCVX)
Price$48.91
Momentum ScoreC
Favorite Metrics
Price vs S&P 500 (26W)-8.11%
Price vs S&P 500 (4W)-14.69%
VGM Score57.12
Market Capitalization$7.42B
All Metrics
Book Value / Share (Quarterly)$20.76
P/TBV (Annual)4.92x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-5.65
Price vs S&P 500 (YTD)0.47%
EPS (TTM)$-6.89
10-Day Avg Trading Volume1.63M
EPS Excl Extra (TTM)$-6.89
EPS (Annual)$-5.63
ROI (Annual)-28.55%
Cash / Share (Quarterly)$12.04
ROA (Last FY)-25.53%
EBITD / Share (TTM)$-7.82
ROE (5Y Avg)-26.74%
Cash Flow / Share (Annual)$-5.44
P/B Ratio2.48x
P/B Ratio (Quarterly)2.80x
Net Income / Employee (Annual)$-1,512,100
Net Interest Coverage (TTM)-41.28x
ROA (TTM)-29.51%
EPS Incl Extra (Annual)$-5.63
Current Ratio (Annual)7.91x
Quick Ratio (Quarterly)7.18x
3-Month Avg Trading Volume1.47M
52-Week Price Return56.71%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$14.95
52-Week High$65.00
EPS Excl Extra (Annual)$-5.63
CapEx CAGR (5Y)117.89%
Tangible BV CAGR (5Y)98.51%
26-Week Price Return7.82%
Quick Ratio (Annual)7.69x
13-Week Price Return-14.33%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)7.49x
Enterprise Value$7.16B
Book Value / Share Growth (5Y)24.80%
Revenue / Employee (Annual)$0
Cash / Share (Annual)$11.91
3-Month Return Std Dev43.44%
Net Income / Employee (TTM)$-1,866,900
ROE (Last FY)-28.55%
Net Interest Coverage (Annual)-35.22x
EPS Basic Excl Extra (Annual)$-5.63
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-6.89
ROI (TTM)-32.51%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$12.00
Price vs S&P 500 (52W)28.50%
Year-to-Date Return11.40%
5-Day Price Return8.67%
EPS Normalized (Annual)$-5.63
ROA (5Y Avg)-24.08%
Month-to-Date Return-10.20%
Cash Flow / Share (TTM)$-3.25
EBITD / Share (Annual)$-6.67
LT Debt / Equity (Annual)0.01x
ROI (5Y Avg)-26.74%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-6.89
P/TBV (Quarterly)3.35x
P/B Ratio (Annual)2.25x
Book Value / Share (Annual)$20.49
Price vs S&P 500 (13W)-24.08%
Beta1.25x
Revenue / Share (TTM)$0.00
ROE (TTM)-32.51%
52-Week Low$29.08
mGradeC
vgmGradeC
Show chart for
Earnings Surprise History
Q1 26-2.30est. -1.79
Analyst Recommendations
Feb 2026
Mar 2026
Apr 2026
May 2026
4.29
4.29
4.29
4.29
Industry Peers — Biological Products(178)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
PCVXVaxcyte, Inc. Common Stock | — | — | C | $48.91 |
| AMGNAmgen Inc | C | C | C | $329.13 |
| GILDGilead Sciences Inc | C | B | C | $131.10 |
| ARGXargenx SE American Depositary Shares | D | A | C | $836.09 |
| RVMDRevolution Medicines, Inc. Common Stock | F | — | A | $163.68 |
| BIIBBiogen Inc. Common Stock | B | D | B | $192.23 |
| BNTXBioNTech SE American Depositary Share | C | C | C | $91.70 |
| MRNAModerna, Inc. Common Stock | C | B | B | $46.06 |
| NBIXNeurocrine Biosciences Inc | C | B | B | $161.00 |
| EXELExelixis Inc | C | B | B | $50.28 |
| KRYSKrystal Biotech, Inc. Common Stock | D | B | B | $298.10 |
About
Vaxcyte is a clinical-stage biopharmaceutical company developing novel vaccines against bacterial infections, including pneumococcal disease, Group A Streptococcus, and Shigella. The company leverages its proprietary XpressCF cell-free protein synthesis platform to design advanced conjugate and protein vaccine candidates for both adult and pediatric populations. Its pipeline includes multiple vaccine programs at various development stages targeting significant public health needs.